BROOKLYN, N.Y.– Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company currently focused on exploring the role that cytokine and gene editing/cell therapy can have in treating…

News from Disruptive capital GP Limited